Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma

Clinical trial NCT06342167 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06342167
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced Esophageal Squamous Cell Carcinoma Sintilimab Radiotherapy Concurrent Chemoradiotherapy Immunonutrition

Start date: 2024-03-14
Primary completion: 2026-07-01
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.